Jennifer Hantson

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies

Bruno Permanne, Astrid Sand, Solenne Ousson et al. · ACS Chemical Neuroscience · 2022 · 75 citations · Full text

Life Sciences, Biochemistry, Neuroscience +17

Glycosaminoglycan analogs as a novel anti-inflammatory strategy

India C. Severin, Adriano Leite Soares, Jennifer Hantson et al. · Frontiers in Immunology · 2012 · 46 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

O1‐12‐05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O‐GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES

J. Michael Ryan, Anna Quattropani, Khalid Abd‐Elaziz et al. · Alzheimer s & Dementia · 2018 · 33 citations

Life Sciences, Neuroscience, Pharmacology +17

Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue™ to monitor the effects of different anti-angiogenic therapies

Anne Broillet, Jennifer Hantson, Curzio Rüegg et al. · Academic Radiology · 2005 · 28 citations

Medicine, Cancer Biology, Oncology +14

O3‐04‐04: Pharmacological intervention with the novel o‐glcnacase inhibitor ASN‐561 reduces pathological tau in transgenic mice

Bruno Permanne, Anna Quattropani, Jennifer Hantson et al. · Alzheimer s & Dementia · 2015 · 14 citations

Life Sciences, Neuroscience, Pharmacology +17